Long-term medication for ADHD (LMA) trial : 2-year prospective observational study in children and adolescents. Core symptoms, daily functioning, and comorbidity outcomes
© 2024. The Author(s)..
More knowledge is needed about long-term ADHD medication and symptom, daily functioning, comorbidity, and tolerability outcomes. This "Long-term Medication for ADHD (LMA) trial" was a prospective observational 2-year trial in children and adolescents aged 6-18 years (extension of 1-year trial). Participants met criteria for DSM-5 ADHD (inattentive or combined), with complex comorbidities; autism spectrum disorder (31%), autistic traits (24%), oppositional symptoms (59%), anxiety (32%), dyslexia/language disorder (16%), borderline intellectual functioning (17%). Medication was individually tailored and followed-up at clinical visits (1, 2, 3, 6, 12, 18, 24 months). Primary outcome: Clinical Global Impression-Severity and Improvement scales (CGI-S, CGI-I). Secondary outcomes: Investigator-rated ADHD-Rating Scale, Weiss Functional Impairment Rating Scale-Parent report (WFIRS-P; Family, School Learning and Behavior, Life Skills, Self-Concept, Social Activities, and Risky Activities domains), comorbidity symptoms and adverse events (AEs). One hundred twenty-eight participants were enrolled (1-year trial only n = 27, LMA trial n = 101). Of these 29 (23%) discontinued, mainly due to AEs (n = 7), moving (n = 7), or no longer needing medication (n = 6). Main AEs were poor appetite, low mood, anxiety, irritability, fatigue. Improvements from baseline to 2 years were large in CGI-S (effect size (ES) 2.28), ADHD-RS (ES 2.06), and moderate to large in WFIRS-P (ES total 0.73, learning 0.4, family 0.67). Overall, the trial showed robust and sustained improvements in ADHD symptom severity and daily functioning over a period of 2 years of ADHD medication in children and adolescents with ADHD and complex comorbidities. Most AEs were mild. Comorbidity symptoms were improved after 1 year, particularly oppositional symptoms, depression, and anxiety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European archives of psychiatry and clinical neuroscience - (2024) vom: 27. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Johnson, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADHD |
|---|
| Anmerkungen: |
Date Revised 27.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00406-023-01744-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367713578 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367713578 | ||
| 003 | DE-627 | ||
| 005 | 20240128232205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240128s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00406-023-01744-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM367713578 | ||
| 035 | |a (NLM)38280948 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnson, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term medication for ADHD (LMA) trial |b 2-year prospective observational study in children and adolescents. Core symptoms, daily functioning, and comorbidity outcomes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a More knowledge is needed about long-term ADHD medication and symptom, daily functioning, comorbidity, and tolerability outcomes. This "Long-term Medication for ADHD (LMA) trial" was a prospective observational 2-year trial in children and adolescents aged 6-18 years (extension of 1-year trial). Participants met criteria for DSM-5 ADHD (inattentive or combined), with complex comorbidities; autism spectrum disorder (31%), autistic traits (24%), oppositional symptoms (59%), anxiety (32%), dyslexia/language disorder (16%), borderline intellectual functioning (17%). Medication was individually tailored and followed-up at clinical visits (1, 2, 3, 6, 12, 18, 24 months). Primary outcome: Clinical Global Impression-Severity and Improvement scales (CGI-S, CGI-I). Secondary outcomes: Investigator-rated ADHD-Rating Scale, Weiss Functional Impairment Rating Scale-Parent report (WFIRS-P; Family, School Learning and Behavior, Life Skills, Self-Concept, Social Activities, and Risky Activities domains), comorbidity symptoms and adverse events (AEs). One hundred twenty-eight participants were enrolled (1-year trial only n = 27, LMA trial n = 101). Of these 29 (23%) discontinued, mainly due to AEs (n = 7), moving (n = 7), or no longer needing medication (n = 6). Main AEs were poor appetite, low mood, anxiety, irritability, fatigue. Improvements from baseline to 2 years were large in CGI-S (effect size (ES) 2.28), ADHD-RS (ES 2.06), and moderate to large in WFIRS-P (ES total 0.73, learning 0.4, family 0.67). Overall, the trial showed robust and sustained improvements in ADHD symptom severity and daily functioning over a period of 2 years of ADHD medication in children and adolescents with ADHD and complex comorbidities. Most AEs were mild. Comorbidity symptoms were improved after 1 year, particularly oppositional symptoms, depression, and anxiety | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADHD | |
| 650 | 4 | |a Autism | |
| 650 | 4 | |a Comorbidities | |
| 650 | 4 | |a Daily functioning | |
| 650 | 4 | |a Long-term medication | |
| 700 | 1 | |a Johnels, J Åsberg |e verfasserin |4 aut | |
| 700 | 1 | |a Östlund, S |e verfasserin |4 aut | |
| 700 | 1 | |a Jakobsson, K |e verfasserin |4 aut | |
| 700 | 1 | |a Högstedt, J |e verfasserin |4 aut | |
| 700 | 1 | |a Larsson, P Javid |e verfasserin |4 aut | |
| 700 | 1 | |a Gillberg, C |e verfasserin |4 aut | |
| 700 | 1 | |a Billstedt, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of psychiatry and clinical neuroscience |d 1996 |g (2024) vom: 27. Jan. |w (DE-627)NLM012966681 |x 1433-8491 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00406-023-01744-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 01 | ||